EP2281873A1 - Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung - Google Patents

Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung Download PDF

Info

Publication number
EP2281873A1
EP2281873A1 EP10175914A EP10175914A EP2281873A1 EP 2281873 A1 EP2281873 A1 EP 2281873A1 EP 10175914 A EP10175914 A EP 10175914A EP 10175914 A EP10175914 A EP 10175914A EP 2281873 A1 EP2281873 A1 EP 2281873A1
Authority
EP
European Patent Office
Prior art keywords
medium
media
buffer
subgroup
supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10175914A
Other languages
English (en)
French (fr)
Other versions
EP2281873B1 (de
Inventor
Richard Fike
William Whitford
William Biddle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of EP2281873A1 publication Critical patent/EP2281873A1/de
Application granted granted Critical
Publication of EP2281873B1 publication Critical patent/EP2281873B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0025—Culture media for plant cell or plant tissue culture

Definitions

  • the present invention relates generally to cells, nutritive media, media supplements, media subgroups and buffer formulations.
  • the present invention provides dry powder nutritive medium formulations, particularly cell culture medium formulations, comprising all ofthe necessary nutritive factors that facilitate the in vitro cultivation of cells, and methods of production of these media formulations.
  • the invention also relates to methods of producing dry powder media supplements, such as dry powder sera (e.g ., fetal bovine serum).
  • dry powder buffer formulations that produce particular ionic and pH conditions upon rehydration.
  • the invention also relates to methods of producing dry powder cells, such as prokaryotic (e.g.
  • the invention also relates to methods of preparing sterile dry powder nutritive media, media supplements (particularly dry powder sera), media subgroups and buffer formulations,
  • the invention also relates to dry powder nutritive media, media supplements, media subgroups, buffer formulations and cells prepared by these method
  • the present invention also relates to kits and methods for cultivation of prokaryotic and eukaryotic cells using these dry powder nutritive media, media supplements, media subgroups and buffer formulations
  • Cell culture media provide the nutrients necessary to maintain and grow cells in a controlled, artificial and in vitro environment Characteristics and compositions of the cell culture media vary depending on the particular cellular requirements. Important parameters include osmolality, pH, and nutrient formulations.
  • Typical components of cell culture media include amino acids, organic and inorganic salts, vitamins, trace metals, sugars, lipids and nucleic acids, the types and amounts of which may vary depending upon the particular requirements of a given cell or tissue type.
  • stability problems result in toxic products and/or lower effective concentrations of required nutrients, thereby limiting the functional life-span ofthe culture media.
  • glutamine is a constituent of almost all media that are used in culturing of mammalian cells in vitro. Glutamine decomposes spontaneously into pyrolidonecarboxylic acid and ammonia. The rate of degradation can be influenced by pH and ionic conditions but in cell culture media, formation of these breakdown products often cannot be avoided ( Tritsch et al., Exp. Cell Res. 28:360-364(1962 ))
  • dry powder media formulations may increase the shelf-life of some media, there are a number of problems associated with dry powdered media, especially in large scale application. Production of large media volumes requires storage facilities for the dry powder media, not to mention the specialized media kitchens necessary to mix and weigh the nutrient components Due to the corrosive nature of dry powder media, mixing tanks must be periodically replaced.
  • cell culture media formulations are supplemented with a range of additives, including undefined components such as fetal bovine serum (FBS) (10-20% v/v) or extracts from animal embryo, organs or glands (0.5-10% v/v), While FBS is the most commonly applied supplement in animal cell culture media, other serum sources are also routinely used, including newborn calf, horse and human.
  • FBS fetal bovine serum
  • Organs or glands that have been used to prepare extracts for the supplementation of culture media include submaxillary gland ( Cohen, S., J. Biol. Chem. 237:1555-1565 (1961 )), pituitary ( Peehl, D.M., and Ham, R.G., In Vitro 16:516-525 (1980 ); U.S.
  • these supplements provide carriers or chelators for labile or water-insoluble nutrients; bind and neutralize toxic moieties; provide hormones and growth factors, protease inhibitors and essential, often unidentified or undefined low molecular weight nutrients; and protect cells from physical stress and damage.
  • serum or organ/gland extracts are commonly used as relatively low-cost supplements to provide an optimal culture medium for the cultivation of animal cells,
  • Culture media are typically produced in liquid form or in powdered form. Each of these forms has particular advantages and disadvantages.
  • liquid culture medium has the advantage that it is provided ready-to-use (unless supplementation with nutrients or other components is necessary), and that the formulations have been optimized for particular cell types
  • Liquid media have the disadvantages, however, that they often do require the addition of supplements (e.g ., L-glutamine, serum, extracts, cytokines, lipids, etc.) for optimal performance in cell cultivation.
  • supplements e.g ., L-glutamine, serum, extracts, cytokines, lipids, etc.
  • liquid medium is often difficult to sterilize economically, since many of the components are heat labile (thus obviating the use of autoclaving, for example) and bulk liquids are not particularly amenable to penetrating sterilization methods such as gamma or ultraviolet irradiation; thus, liquid culture media are most often sterilized by filtration, which can become a time-consuming and expensive process. Furthermore, production and storage of large batch sizes ( e.g ., 1000 liters or more) of liquid culture media are impractical, and the components of liquid culture media often have relatively short shelf lives.
  • liquid culture medium can be formulated in concentrated form; these media components may then be diluted to working concentrations prior to use.
  • This approach provides the capability of making larger and variable batch sizes than with standard culture media, and the concentrated media formulations or components thereof often have longer shelf-life (see U.S.. Patent No. 5,474,931 . which is directed to culture media concentrate technology).
  • concentrated liquid media still have the disadvantages of their need for the addition of supplements (e.g ., FBS, L-glutamine or organ/gland extracts), and may be difficult to sterilize economically.
  • powdered culture media are often used. Powdered media are typically produced by admixing the dried components ofthe culture medium via a mixing process, e.g ., ball-milling, or by lyophilizing pre-made liquid culture medium. This approach has the advantages that even larger batch sizes may be produced, the powdered media typically have longer shelf lives than liquid media, and the media can be sterilized by irradiation (e.g ., gamma or ultraviolet irradiation) or ethylene oxide permeation after formulation.
  • irradiation e.g ., gamma or ultraviolet irradiation
  • ethylene oxide permeation ethylene oxide permeation after formulation.
  • powdered media have several distinct disadvantages. For example, some of the components of powdered media become insoluble or aggregate upon lyophilization such that resolubilization is difficult or impossible.
  • powdered media typically comprise fine dust particles which can make them particularly difficult to reconstitute without some loss of material, and which may further make them impractical for use in many biotechnology production facilities operating under GMP/GLP, USP or ISO 9000 settings.
  • many of the supplements used in culture media e.g ., L-glutamine and FBS, cannot be added to the culture medium prior to lyophilization or ball-milling due to their instability or propensity to aggregate upon concentration or due to their sensitivity to shearing by processes such as ball-milling.
  • many of these supplements, particularly serum supplements such as FBS show a substantial loss of activity or are rendered completely inactive if attempts are made to produce powdered supplements by processes such as lyophilization.
  • the present invention provides methods for the production of nutritive media, media supplement, media subgroup and buffer powders comprising agglomerating a dry powder nutritive media, media supplement, media subgroup or buffer with a solvent.
  • the invention also relates to methods for the production of powdered nutritive media, media supplements, media subgroups, and buffers, comprising spray-drying a liquid nutritive medium, medium supplement, medium subgroup or buffer under conditions sufficient to produce their dry powder counterparts. Such conditions may, for example, comprise controlling heat and humidity until the powdered media, media supplement, media subgroup or buffer is formed.
  • the method may further comprise sterilizing the nutritive media, media supplement, media subgroup or buffer powder, which may be accomplished prior to or after packaging the powder. In particularly preferred methods, the sterilization is accomplished after packaging of the powder by irradiation of the packaged powder with gamma rays.
  • Particularly preferred nutritive medium powders that may be produced according to the invention include culture medium powders selected from the group consisting of a bacterial culture medium powder, a yeast culture medium powder, a plant culture medium powder and an animal culture medium powder
  • Particularly preferred media supplements that may be produced by the methods of the invention include: powdered animal sera, such as bovine sera (e.g ., fetal bovine, newborn calf or normal calf sera), human sera, equine sera, porcine sera, monkey sera, ape sera, rat sera, murine sera, rabbit sera, ovine sera and the like; cytokines (including growth factors (such as EGF, aFGF, bFGF, HGF, IGF-1, IGF-2, NGF and the like), interleukins, colony-stimulating factors and interferons); attachment factors or extracellular matrix components (such as collagens, laminins, proteoglycans, glycosaminoglycans, fibronectin, vitronectin and the like); lipids (such as phospholipids, cholesterol, bovine cholesterol concentrate, fatty acids, sphingolipids and the like); and extracts of animal tissues, organs or glands (such as bovine pituitary extract,
  • Other media supplements that may be produced by the present methods include a variety of proteins (such as serum albumins, particularly bovine or human serum albumins; immunoglobulins and fragments or complexes thereof; aprotinin; hemoglobin; haemin or haematin; enzymes (such as trypsin, collagenases, pancreatinin or dispase); lipoproteins; ferritin; etc.) which may be natural or recombinant; vitamins; amino acids and variants thereof (including, but not limited to, L-glutamine and cystine), enzyme co-factors and other components useful in cultivating cells in vitro that will be familiar to one of ordinary skill.
  • proteins such as serum albumins, particularly bovine or human serum albumins; immunoglobulins and fragments or complexes thereof; aprotinin; hemoglobin; haemin or haematin; enzymes (such as trypsin, collagenases, pancreatinin or dispase); lipoproteins; ferritin;
  • the nutritive media and media supplements prepared by the invention may also comprise subgroups such as serum (preferably those described above), L-glutamine, insulin, transferrin, one or more lipids (preferably one or more phospholipids, sphingolipids, fatty acids or cholesterol), one or more cytokines (preferably those described above), one or more neurotransmitters, one or more extracts of animal tissues, organs or glands (preferably those described above), one or more proteins (preferably those described above) or one or more buffers (preferably sodium bicarbonate), or any combination thereof.
  • serum preferably those described above
  • L-glutamine lipids
  • lipids preferably one or more phospholipids, sphingolipids, fatty acids or cholesterol
  • cytokines preferably those described above
  • neurotransmitters preferably those described above
  • extracts of animal tissues, organs or glands preferably those described above
  • proteins preferably those described above
  • buffers preferably sodium bicarbonate
  • Buffer powders particularly suitable for preparation according to the methods of the invention include buffered saline powders, most particularly phosphate-buffered saline powders or Tris-buffered saline powders.
  • the invention also provides nutritive medium powders, medium supplement powders (including powders ofthe above-described supplements) and buffer powders prepared according to these methods.
  • the invention also relates to methods of preparing dried cells, including prokaryotic (e.g. , bacterial) and eukaryotic (e.g ., fungal (especially yeast), animal (especially mammalian, including human) and plant) cells, comprising obtaining a cell to be dried, contacting the cell with one or more stabilizers (e.g. , a polysaccharide such as trehalose), forming an aqueous suspension comprising the cell, and spray-drying the cell suspension under conditions favoring the production of a dried powder,
  • prokaryotic e.g. , bacterial
  • eukaryotic e.g., fungal (especially yeast)
  • animal especially mammalian, including human
  • plant comprising obtaining a cell to be dried, contacting the cell with one or more stabilizers (e.g. , a polysaccharide such as trehalose), forming an aqueous suspension comprising the cell, and spray-drying the cell suspension under conditions favor
  • the invention further relates to methods of preparing sterile powdered culture media, media supplements, media subgroups and buffers.
  • One such method comprises exposing the above-described powdered culture media, media supplements, media subgroups and buffers to ⁇ irradiation such that bacteria, fungi, spores and viruses that may be resident in the powders are rendered incapable of replication.
  • the powdered media, media supplements, media subgroups and buffers are ⁇ irradiated at a total dosage of about 10-100 kilograys (kGy), preferably a total dosage of about 15-75 kGy, 15-50 kGy, 15-40 kGy or 20-40 kGy, more preferably a total dosage of about 20-30 kGy, and most preferably a total dosage of about 25 kGy, for about I hour to about 7 days, preferably for about 1 hour to about 5 days, more preferably for about 1 hour to about 3 days, about 1 hour to about 24 hours or about 1-5 hours, and most preferably about 1-3 hours.
  • the invention also relates to sterile powdered culture media, media supplements, media subgroups and buffers produced by these methods.
  • the invention further provides methods of culturing a cell comprising reconstituting the nutritive media, media supplement, media subgroup or buffer of the invention with a solvent, which preferably comprises serum or water, and contacting the cell with the reconstituted nutritive media, media supplement, media subgroup or buffer under conditions favoring the cultivation of the cell.
  • a solvent which preferably comprises serum or water
  • Any cell may be cultured according to the present methods, particularly bacterial cells, yeast cells, plant cells or animal cells.
  • Preferable animal cells for culturing by the present methods include insect cells (most preferably Drosophila cells, Spodoptera cells and Trichoplusa cells), nematode cells (most preferably C.
  • elegans cells and mammalian cells (most preferably CHO cells, COS cells, VERO cells, BHK cells, AE-1 cells, SP2/0 cells, L5.1 cells, hybridoma cells or human cells).
  • Cells cultured according to this aspect of the invention may be normal cells, diseased cells, transformed cells, mutant cells, somatic cells, germ cells, stem cells, precursor cells or embryonic cells, any of which may be established cell lines or obtained from natural sources.
  • Kits according to the invention may comprise one or more containers containing one or more of the nutritive media powders, media supplement powders, media subgroup powders or buffer powders of the invention, or any combination thereof
  • the kits may also comprise one or more cells or cell types, including the dried cell powders of the invention.
  • binder refers to a composition that is present in granular form, which may or may not be complexed or agglomerated with a solvent such as water or serum
  • dry powder may be used interchangeably with the term “powder;” however, “dry powder” as used herein simply refers to the gross appearance of the granulated material and is not intended to mean that the material is completely free of complexed or agglomerated solvent unless otherwise indicated.
  • ingredients refers to any compound, whether of chemical or biological origin, that can be used in cell culture media to maintain or promote the growth of proliferation of cells.
  • component e.g., fetal calf serum
  • ingredient e.g., calf serum, calf serum, calf serum, calf serum, calf serum, calf serum, calf serum, calf serum, calf serum, calf serum, calf serum, calfate, calfate, calfate, arate, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate, calfate,
  • cytokine refers to a compound that induces a physiological response in a cell, such as growth, differentiation, senescence, apoptosis, cytotoxicity or antibody secretion. Included in this definition of "cytokine” are growth factors, interleukins, colony-stimulating factors, interferons and lymphokines.
  • cell culture or “culture” is meant the maintenance of cells in an artificial, e.g ., an in vitro environment
  • the term “cell culture” is a generic term and may be used to encompass the cultivation not only of individual prokaryotic (e.g , bacterial) or eukaryotic (e.g ., animal, plant and fungal) cells, but also of tissues, organs, organ systems or whole organisms, for which the terms “tissue culture,” “organ culture,” “organ system culture” or “organotypic culture” may occasionally be used interchangeably with the term “cell culture.”
  • cultivation is meant the maintenance of cells in an artificial environment under conditions favoring growth, differentiation or continued viability, in an active or quiescent state, of the cells.
  • cultivation may be used interchangeably with “cell culture” or any of its synonyms described above.
  • culture vessel is meant a glass, plastic, or metal container that can provide an aseptic environment for culturing cells.
  • cell culture medium refers to a nutritive solution that supports the cultivation and/or growth of cells; these phrases may be used interchangeably
  • extract is meant a composition comprising a concentrated preparation of the subgroups of a substance, typically formed by treatment of the substance either mechanically (e.g ., by pressure treatment) or chemically (e.g. , by distillation, precipitation, enzymatic action or high salt treatment).
  • enzyme digest a composition comprising a specialized type of extract, namely one prepared by treating the substance to be extracted (e.g. , plant components or yeast cells) with at least one enzyme capable of breaking down the components of the substance into simpler forms (e.g. , into a preparation comprising mono- or disaccharides and/or mono-, di- or tripeptides).
  • substance to be extracted e.g. , plant components or yeast cells
  • enzyme capable of breaking down the components of the substance into simpler forms e.g. , into a preparation comprising mono- or disaccharides and/or mono-, di- or tripeptides.
  • hydrolysate may be used interchangeably with the term “enzymatic digest.
  • contacting refers to the placing of cells to be cultivated into a culture vessel with the medium in which the cells are to be cultivated.
  • the term “contacting” encompasses mixing cells with medium, pipetting medium onto cells in a culture vessel, and submerging cells in culture medium.
  • combining refers to the mixing or admixing of ingredients in a cell culture medium formulation.
  • a cell culture medium is composed of a number of ingredients and these ingredients vary from one culture medium to another.
  • a "1X formulation” is meant to refer to any aqueous solution that contains some or all ingredients found in a cell culture medium at working concentrations
  • the “1X formulation” can refer to, for example, the cell culture medium or to any subgroup of ingredients for that medium
  • the concentration of an ingredient in a 1X solution is about the same as the concentration of that ingredient found in a cell culture formulation used for maintaining or cultivating cells in vitro.
  • a cell culture medium used for the in vitro cultivation of cells is a 1X formulation by definition. When a number of ingredients are present, each ingredient in a 1X formulation has a concentration about equal to the concentration ofthose ingredients in a cell culture medium.
  • RPMI-1640 culture medium contains, among other ingredients, 0.2 g/L L-arginine, 0.05 g/L L-asparagine, and 0.02 g/L L-aspartic acid.
  • a "1X formulation" of these amino acids contains about the same concentrations of these ingredients in solution
  • each ingredient in solution has the same or about the same concentration as that found in the cell culture medium being described.
  • concentrations of ingredients in a 1X formulation of cell culture medium are well known to those of ordinary skill in the art. See Methods For Preparation of Media, Supplements and Substrate For Serum-Free Animal Cell Culture Allen R. Liss, N.Y. (1984 ), which is incorporated by reference herein in its entirety.
  • the osmolality and/or pH may differ in a 1X formulation compared to the culture medium, particularly when fewer ingredients are contained in the 1X formulation.
  • a "10X formulation” is meant to refer to a solution wherein each ingredient in that solution is about 10 times more concentrated than the same ingredient in the cell culture medium.
  • a 10X formulation of RPMI-1640 culture medium may contain, among other ingredients, 2.0 g/L L-arginine, 0.5 g/L L-asparagine, and D.2 g/L L-aspartic acid (compare 1X formulation, above)
  • a "10X formulation” may contain a number of additional ingredients at a concentration about 10 times that found in the I X culture medium.
  • the present invention is directed to methods of producing nutritive media, media supplements, media subgroups or buffer.
  • Nutritive media, media supplements and media subgroups produced by the present methods are any media, media supplement or media subgroup (serum-free or serum-containing) which may be used to support the growth of a cell, which may be a bacterial cell, a fungal cell (particularly a yeast cell), a plant cell or an animal cell (particularly an insect cell, a nematode cell or a mammalian cell, most preferably a human cell), any of which may be a somatic cell, a germ cell, a normal cell, a diseased cell, a transformed cell, a mutant cell, a stem cell, a precursor cell or an embryonic cell.
  • Preferred such nutritive media include, but are not limited to, cell culture media, most preferably a bacterial cell culture medium, plant cell culture medium or animal cell culture medium.
  • Preferred media supplements include, but are not limited to, undefined supplements such as extracts of bacterial, animal or plant cells, glands, tissues or organs (particularly bovine pituitary extract, bovine brain extract and chick embryo extract); and biological fluids (particularly animal sera, and most preferably bovine serum (particularly fetal bovine, newborn calf or normal calf serum), horse serum, porcine serum, rat serum, murine serum, rabbit serum, monkey serum, ape serum or human serum, any of which may be fetal serum) and extracts thereof (more preferably serum albumin and most preferably bovine serum albumin or human serum albumin).
  • Medium supplements may also include defined replacements such as LipoMAX®, OptiMAb®, Knock-OutTM SR (each available from Life Technologies, Inc., Rockville, Maryland), and the like, which can be used as substitutes for the undefined media supplements described above.
  • Such supplements may also comprise defined components, including but not limited to, hormones, cytokines, neurotransmitters, lipids, attachment factors, proteins and the like.
  • Nutritive media can also be divided into various subgroups (see U.S. Patent No. 5,474,931 ) which can be prepared by, and used in accordance with, the methods of the invention. Such subgroups can be combined to produce the nutritive media of the present invention.
  • any nutritive media, media supplement, media subgroup or buffer may be produced and stored for an extended period of time without significant loss of biological and biochemical activity.
  • “without significant loss of biological and biochemical activity” is meant a decrease of less than about 30%, preferably less than about 25%, more preferably less than about 20%, still more preferably less than about 15%, and most preferably less than about 10%, of the biological or biochemical activity of the nutritive media, media supplement, media subgroup or buffer when compared to a freshly made nutritive media, media supplement, media subgroup or buffer of the same formulation
  • extended period of time is meant a period of time longer than that for which a nutritive medium, supplement, subgroup or buffer is stored when prepared by traditional methods such as ball-milling.
  • an "extended period of time” therefore means about 1-36 months, about 2-30 months, about 3-24 months, about 6-24 months, about 9-18 months, or about 4-12 months, under a given storage condition, which may include storage at temperatures of about -70°C to about 25 °C, about -20°C to about 25°C, about 0°C to about 25°C, about 4°C to about 25°C, about 10°C to about 25°C, or about 20°C to about 25°C
  • Assays for determining the biological or biochemical activity of a nutritive media, media supplement, media subgroup or buffer are well-known in the art and are familiar to one of ordinary skill.
  • Any nutritive media, media supplement, media subgroup or buffer may be prepared by the methods ofthe present invention.
  • Particularly preferred nutritive media, media supplements and media subgroups that may be prepared according to the invention include cell culture media, media supplements and media subgroups that support the growth of animal cells, plant cells, bacterial cells or yeast cells.
  • Particularly preferred buffers that may be prepared according to the invention include balanced salt solutions which are isotonic for animal cells, plant cells, bacterial cells or yeast cells.
  • animal cell culture media examples include, but are not limited to, DMEM, RPMI-1640, MCDB 131, MCDB 153, M17EM, IMDM, MEM, M199, McCoy's 5A, Williams' Media E, Leibovitz's 1,-15 Medium, Grace's Insect Medium, IPL-41 Insect Medium, TC-100 Insect Medium, Schneider's Drosophila Medium, Wolf & Quimby's Amphibian Culture Medium, cell-specihc serum-free media (SPM) such as those designed to support the culture of keratinocytes, endothelial cells, hepatocytes, melanocytes, etc., F10 Nutrient Mixture and F12 Nutrient Mixture
  • Other media, media supplements and media subgroups suitable for preparation by the invention are available commercially (e.g ., from Life Technologies, Inc.; Rockville, Maryland, and Sigma; St.
  • plant cell culture media examples include, but are not limited to, Anderson's Plant Culture Media, CLC Basal Media, Gamborg's Media, Guillard's Marine Plant Culture Media, Provasoli's Marine Media, Kao and Michayluk's Media, Murashige and Skoog Media, McCown's Woody Plant Media, Knudson Orchid Media, Lindemann Orchid Media, and Vacin and Went Media.
  • Formulations for these media which are commercially available, as well as for many other commonly used plant cell culture media, are well-known in the art and may be found for example in the Sigma Plant Cell Culture Catalogue (Sigma; St. Louis, Missouri).
  • bacterial cell culture media examples include, but are not limited to, Trypticase Soy Media, Brain Heart Infusion Media, Yeast Extract Media, Peptone-Yeast Extract Media, BeefInfusion Media, ThioglycollateMedia, Indoie-Nitrate Media, MR-VP Media, Simmans'Citrate Media, CTA Media, Bile Esculin Media, Bordet-Gengou Media, Charcoal Yeast Extract (CYE) Media, Mannital-salt Media, MacConkey's Media, Eosin-methylene blue (EMB) media, Thayer-Martin Media, Salmonella-Shigella Media, and Urease Media.
  • Trypticase Soy Media Brain Heart Infusion Media
  • Yeast Extract Media Peptone-Yeast Extract Media
  • BeefInfusion Media ThioglycollateMedia
  • Indoie-Nitrate Media MR-VP Media
  • Simmans'Citrate Media CTA Media
  • Bile Esculin Media Bordet-Gengou Media
  • Formulations for these media which are commercially available, as well as for many other commonly used bacterial cell culture media, are well-known in the art and may be found for example in the DIFCO Manual (DIFCO; Norwood, Massachusetts) and in the Manual of Clinical Microbiology (American Society for Microbiology, Washington, DC).
  • yeast cell culture media examples include, but are not limited to, Sabouraud Media and Yeast Morphology Media (YMA).
  • YMA Yeast Morphology Media
  • Formulations for these media, which are commercially available, as well as for many other commonly used yeast cell culture media, are well-known in the art and may be found for example in the DIFCO Manual (DIFCO; Norwood, Massachusetts) and in the Manual of Clinical Microbiology (American Society for Microbiology, Washington, DC).
  • any of the above media of the invention may also include one or more additional components, such as indicating or selection agents (e.g ., dyes, antibiotics, amino acids, enzymes, substrates and the like), filters (e.g ., charcoal), salts, polysaccharides, ions, detergents, stabilizers, and the like.
  • indicating or selection agents e.g ., dyes, antibiotics, amino acids, enzymes, substrates and the like
  • filters e.g ., charcoal
  • the above-described culture media may comprise one or more buffer salts, preferably sodium bicarbonate, at concentrations sufficient to provide optimal buffering capacity for the culture medium.
  • a buffer salt such as sodium bicarbonate, may be added in powdered form to the powdered medium prior to, during or following agglomeration of the medium.
  • the sodium bicarbonate may be added to the culture medium prior to, during or following agglomeration with an appropriate solvent (such as water, serum or a pH-adjusting agent such as an acid (e,g., HCl at a concentration of 1M to 5M, preferably at 1M) or a base ( e.g ., NaOH at a concentration of 1M to 5M, preferably at 1M) such that, upon reconstitution of the agglomerated medium the culture medium is at the optimal or substantially optimal pH for cultivation of a variety of cell types
  • an appropriate solvent such as water, serum or a pH-adjusting agent such as an acid (e,g., HCl at a concentration of 1M to 5M, preferably at 1M) or a base (e.g ., NaOH at a concentration of 1M to 5M, preferably at 1M)
  • an appropriate solvent such as water, serum or a pH-adjusting agent such as an acid (e,g., HCl at a concentration of 1M to 5M,
  • one or more buffer salts may be added directly to a powdered nutritive medium by agglomerating the buffer(s) into the medium using a fluid bed apparatus, or by spray-drying the buffer(s) onto a dry or agglomerated powdered medium (using a spray-drying apparatus as described below).
  • a pH-adjusting agent such as an acid (e.g., HCl) or a base (e.g ., NaOH) may be added to a powdered nutritive medium, which may contain one or more buffer salts (such as sodium bicarbonate), by agglomeration of the pH-adjusting agent into the powdered nutritive medium in a fluid bed apparatus, by spray-drying the pH-adjusting agent onto the powdered or agglomerated nutritive medium, or by a combination thereof; this approach obviates the subsequent addition of a pH-adjusting agent after reconstitution of the powdered medium
  • the invention provides a powdered nutritive culture medium useful in cultivation or growth of cells in vitro that, upon reconstitution with a solvent (e.g ., water or serum), has a pH that is optimal for the support of cell cultivation or growth without a need for adjustment of the pH of the liquid medium.
  • a solvent e.g ., water or serum
  • a mammalian cell culture medium prepared according to these methods may, upon reconstitution, have a pH of between about 7.1 to about 7.5, more preferably between about 7.1 to about 7.4, and most preferably about 7.2 to about 7.4 or about 7.2 to about 7.3.
  • the preparation of one example of such an automatically pH-adjusting culture medium is shown in more detail below in Examples 3 and 6.
  • Examples of media supplements that may be prepared as powders by the present methods include, without limitation, animal sera (such as bovine sera (e.g ., fetal bovine, newborn calf and calf sera), human sera, equine sera, porcine sera, monkey sera, ape sera, rat sera, murine sera, rabbit sera, ovine sera and the like), defined replacements such as LipoMAX®, OptiMAb®, Knock-OutTM SR (each available from Life Technologies, Inc., Rockville, Maryland), hormones (including steroid hormone such as corticosteroids, estrogens, androgens ( e.g ., testosterone) and peptide hormones such as insulin, cytokines (including growth factors ( e.g ., EGF, aFGF, bFGF, HGF, IGF-1, IGF-2, NGF and the like), interleukins, colony-stimulating factors, interferons and the like), neurotransmitters, lipids including phospholipids
  • Other media supplements that may be produced by the present methods include a variety of proteins (such as serum albumins, particularly bovine or human serum albumins; immunoglobulins and fragments or complexes thereof; aprotinin; hemoglobin; haemin or haematin; enzymes (such as trypsin, collagenases, pancreatinin or dispase); lipoproteins; fetuin; ferritin; etc.), which may be natural or recombinant; vitamins; amino acids and variants thereof (including, but not limited to, L-glutamine and cystine), enzyme co-factors; polysaccharides; salts or ions (including trace elements such as salts or ions of molybdenum, vanadium, cobalt, manganese, selenium, and the like); and other supplements and compositions that are useful in cultivating cells in vitro that will be familiar to one of ordinary skill.
  • proteins such as serum albumins, particularly bovine or human serum albumins; immunoglobulins
  • sera and other media supplements are available commercially (for example, from Life Technologies, Inc., Rockville, Maryland, and Sigma Cell Culture, St. Louis, Missouri); alternatively, sera and other media supplements described above may be isolated from their natural sources or produced recombinantly by art-known methods that will be routine to one of ordinary skill (see Freshney, R.I., Culture of Animal Cells, New York: Alan R. Liss, Inc, pp, 74-78 (1983 ), and references cited therein; see also Harlow, E., and Lane, D., Antibodies: A Laboratory Manual, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, pp. 116-120 (1988 )).
  • buffers examples include, but are not limited to, phosphate-buffered saline (PBS) formulations, Tris-buffered saline (FBS) formulations, HEPES-buffered saline (HBS) formulations, Hanks' Balanced Salt Solutions (HBSS), Dulbecco's PBS (DPBS), Earle's Balanced Salt Solutions, Puck's Saline Solutions, Murashige and Skoog Plant Basal Salt Solutions, Keller's Marine Plant Basal Salt Solutions, Provasoli's Marine Plant Basal Salt Solutions, and Kao and Michayluk's Basal Salt Solutions.
  • PBS phosphate-buffered saline
  • FBS Tris-buffered saline
  • HBS HEPES-buffered saline
  • HBSS Hanks' Balanced Salt Solutions
  • DPBS Dulbecco's PBS
  • Earle's Balanced Salt Solutions Puck's Saline Solutions
  • the methods of the present invention provide for the preparation of the above-described powdered nutritive media, media supplements, media subgroups and buffers.
  • These powdered media, supplements, subgroups and buffers are preferably prepared using fluid bed technology (i.e. , "agglomeration") and/or via spray-drying.
  • the powdered nutritive media, media supplements, media subgroups and buffers are prepared using fluid bed technology to agglomerate the solutions of media, media supplements, media subgroups or buffers, thereby producing their dry powdered forms
  • Fluid bed technology is a process of producing agglomerated powders having altered characteristics (particularly, for example, solubility) from the starting materials.
  • powders are suspended in an upwardly moving column of air while at the same time a controlled and defined amount of liquid is injected into the powder stream to produce a moistened state of the powder, mild heat is then used to dry the material, producing an agglomerated powder
  • Apparatuses for producing and/or processing particulate materials by fluid bed technology are available commercially (e.g ., from Niro, Inc./Aeromatic-Fielder; Columbia, Maryland), and are described, for example, in U.S. Patent Nos. 3,771,237 ; 4,885,848 ; 5,133,137 ; 5,357,688 ; and 5,392,531 ; and in WO 95/13867 ; the disclosures of all of the foregoing patents and applications are incorporated by reference herein in their entireties.
  • Such apparatuses have been used to prepare agglomerated powders of various materials, including milk whey ( US Patent No. 5,006,204 ), acidulated meat emulsions ( U.S. Patent No. 4,511,592 ), proteases ( U.S. Patent No 4,689,297 ) and other proteins ( DK 167090 B1 ), and sodium bicarbonate ( U.S. Patent No. 5,325,606 ).
  • fluid bed technology may be used to prepare bulk agglomerated nutritive media, media supplements, media subgroups and buffers
  • a dry powdered nutritive medium, medium supplement or buffer is placed into a fluid bed apparatus and is subjected to agglomeration therein.
  • Powdered nutritive media (particularly powdered cell culture media), powdered media supplements (particularly powdered animal sera) and powdered buffers (particularly powdered buffered salines), may be obtained pre-made from commercial sources (e.g ., Life Technologies, Inc.; Rockville, Maryland)
  • powdered nutritive media, media supplements, media subgroups or buffers may be made by admixing individual components or sets of components according to the formulations described abave.
  • Such formulations may include components which typically are not present in powdered nutritive media, media supplement, media subgroup and buffer formulations due to their instability, such as serum, L-glutamine, cystine, insulin, transferrin, lipids (particularly phospholipids, sphingolipids, fatty acids and cholesterol), cytokines (particularly growth factors, interleukins, colony-stimulating factors and interferons), neurotransmitters and buffers (particularly sodium bicarbonate).
  • L-glutamine is added to the formulation, it may be in the form of a complex with divalent cations such as calcium or magnesium (see U.S. Patent No, 5,474,931 ).
  • two or more powdered components may be admixed and then agglomerated to produce complex media, media supplements, media subgroups or buffers.
  • a powdered nutritive medium may be mixed with a powdered serum (produced, for example, by spray-drying as described below) such as FBS at a serum concentration of about 0.1%, 0.2%, 0.5%, 1%, 2%, 2.5%, 5%, 7.5%,10%,15%, 20%, 25%, 50% or higher (w/w as a percentage of the powdered medium); the resulting powdered medium-serum mixture may then be agglomerated to produce an agglomerated medium-serum complex that will readily dissolve in a reconstituting solvent and thus be ready for use without further supplementation.
  • a powdered nutritive medium may be mixed with a powdered serum (produced, for example, by spray-drying as described below) such as FBS at a serum concentration of about 0.1%, 0.2%, 0.5%, 1%,
  • filters to be used in the invention should be mesh screens that allow air to flow through but that retain the powders, for example filters of about 1-100 mesh, preferably about 2-50 mesh, more preferably about 2.5-35 mesh, still more preferably about 3-20 mesh or about 3.5-15 mesh, and most preferably about 4-6 mesh.
  • the dry powder nutritive media, media supplement, media subgroup or buffer (or mixture thereof) is then subjected to agglomeration by injecting, preferably using a spray nozzle on the fluid bed apparatus, a defined and controlled amount of solvent into the powder, to produce a moistened powder.
  • Preferred solvents for use in the present invention are any solvent that is compatible with the formulation of the nutritive media, media supplement, media subgroup or buffer.
  • compatible is meant that the solvent does not induce irreversible deleterious changes in the physical or performance characteristics of the nutritive media, media supplement, media subgroup or buffer, such as breakdown or aggregation of the nutrient components of the nutritive medium or changes in the ionic characteristics of the buffer.
  • Particularly preferred solvents for use in the invention are water (most particularly distilled and/or deionized water), serum (particularly bovine or human serum and most particularly fetal bovine serum or calf serum), organic solvents (particularly dimethylsulfoxide, acetone, ethanol and the like), any of which may contain one or more additional components (e.g ., salts, polysaccharides, ions, detergents, stabilizers, etc.).
  • water most particularly distilled and/or deionized water
  • serum particularly bovine or human serum and most particularly fetal bovine serum or calf serum
  • organic solvents particularly dimethylsulfoxide, acetone, ethanol and the like
  • any of which may contain one or more additional components (e.g ., salts, polysaccharides, ions, detergents, stabilizers, etc.).
  • the solvent may be desirable or advantageous to include in the solvent one or more ingredients that, due to the concentrations of the components required in the final product, cannot be optimally incorporated into the product by other methods such as ball-milling.
  • the component may be dissolved, suspended, colloided or otherwise introduced into the solvent at the desired concentration, prior to use of the solvent in agglomeration of the powdered media, media supplement, media subgroup or buffer of the invention.
  • Components that may be advantageously incorporated into the solvent in accordance with this aspect of the invention include, but are not limited to, one or more of the above-described sera, hormones, cytokines, neurotransmitters, lipids, attachment factors, proteins, amino acids, vitamins, enzyme cofactors, polysaccharides, salts, ions, buffers and the like.
  • the solvent should be introduced into the dry powder in a volume that is dependent upon the mass of powdered media, media supplement, media subgroup or buffer to be agglomerated.
  • Preferred volumes of solvent per 500 grams of nutritive media, media supplement, media subgroup or buffer are about 5-100 ml, more preferably about 10-50 ml, still more preferably about 25-50 ml, and most preferably about 35 ml.
  • Preferred solvent introduction rates per 500 grams of nutritive media, media supplement, media subgroup or buffer are a rate of about 1-10 ml/min, preferably about 2-8 ml/min, more preferably about 4-8 ml/min and most preferably about 6 ml/min. In some situations, it may be desirable to cycle between adding solvent for about one minute and then not adding solvent for about one minute (allowing drying of the powder within the apparatus chamber), so as to prevent clumping of the powder during agglomeration.
  • the powder is thoroughly dried in the apparatus.
  • Preferred apparatus temperatures for drying of the agglomerated powder are about 50-80°C, more preferably about 55-75°C, and most preferably about 60-65°C; powder is preferably dried in the apparatus for about 3-10 minutes and most preferably for about 5-7 minutes, per 500 grams of powder.
  • powdered nutritive media, media supplements, media subgroups and buffers may be prepared by spray-drying.
  • the nutritive media, media supplements, media subgroups and buffers in their liquid forms are placed into a spray-drying apparatus; these liquids are then converted into their corresponding powders by spraying the solution into a chamber in the apparatus under appropriate conditions to produce the powders, such as under controlled temperature and humidity, until the powders are formed.
  • liquid nutritive media containing animal sera at a desired concentration may be mixed and then prepared as spray-dried powders according to the methods of the invention
  • the liquid nutritive media, media supplements, media subgroups and buffers are aspirated into the apparatus and are atomized into a spray with a rotary- or nozzle-type atomizer.
  • the resulting atomized liquid spray is then mixed with a gas (e.g. , nitrogen or more preferably air) and sprayed into a drying chamber under conditions sufficient to promote production of a powdered product.
  • these conditions may comprise electronic control ofthe temperature and humidity within the chamber such that final drying of the product is promoted.
  • the solvent in the liquid evaporates in a controlled manner, thereby forming free-flowing particles (i.e ., powder) of the nutritive media, media supplements, media subgroups or buffers of the invention.
  • the powder is then discharged from the drying chamber, passed through one or more filters (such as the mesh screens described above for fluid bed preparation) and collected for further processing (e.g., packaging, sterilization, etc.).
  • the spray-drying apparatus may be combined with a fluid bed apparatus integrated within the drying chamber, which allows the introduction of agglomerating solvents such as those described above into the spray-dried powder to produce agglomerated spray-dried powdered nutritive media, media supplements, media subgroups and buffers.
  • Apparatuses for producing particulate materials from liquid materials by spray-drying are available commercially (e.g ., from Niro, Inc./Aeromatic-Fielder; Columbia, Maryland), and are described, for example, in the "Spray Drying," “Powdered Pharmaceuticals by Spray Drying” and “Fresh Options in Drying” technical brochures of Niro, Inc./Aeromatic-Fielder, the disclosures of which are incorporated by reference herein in their entireties.
  • spray-drying has been found to be particularly useful for the preparation of powdered media supplements, such as sera and in particular those sera described above, most particularly human and bovine sera (such as fetal bovine serum and calf serum).
  • the liquid nutritive media, media supplements, media subgroups, butters or pH-adjusting agents should be sprayed into the chamber through the atomizer at a spray rate of about 25-100 g/min, preferably at a spray rate of about 30-90 g/min, 35-85 g/min, 40-80 g/min, 45-75 g/min, 50-75 g/min, 55-70 g/min, or 60-65 g/min, and more preferably at about 65 g/min.
  • the inlet air temperature in the atomizer is preferably set at about 100-300 °C, more preferably at about 150-250 °C, and most preferably at about 200°C, with an outlet temperature of about 50-100°C, more preferably about 60-80°C, and most preferably about 70°C.
  • Air flow in the atomizer is preferably set at about 50-100 kg/hr, more preferably about 75-90 kg/hr, and most preferably about 80.0 kg/hr, at a nozzle pressure of about 1-5 bar, more preferably about 2-3 bar, and most preferably about 2.0 bar.
  • the spray-dried powdered nutritive media, media supplements, media subgroups or buffers may be collected in the drying chamber through one or more filters, preferably such as those described above for fluid bed technology.
  • the powders of the invention prepared by the above-described fluid bed or spray-drying methods have altered physical characteristics from the starting powders or from powdered media, supplements, subgroups and buffers prepared by lyophilizing the corresponding liquids.
  • non-processed or lyophilized powders often produce significant dust when used, and dissolve poorly or slowly in various solvents, while agglomerated or spray-dried powders are substantially dust-free and/or dissolve rapidly.
  • the powdered media, media supplements, media subgroups and buffers of the invention will exhibit both reduced dusting and more rapid dissolution than their powdered counterparts prepared by standard techniques such as ball-milling.
  • the powders may be rapidly dissolved by rapid mechanical solvation ofthe powder, such as using a mechanical impeller, or by first providing a solvent mist over the powder such as by spray solvation.
  • the spray-drying and agglomeration approaches described above may be combined to produce agglomerated spray-dried nutritive media, media supplement, media subgroup and buffer powders.
  • a powdered medium, supplement, subgroup or buffer that has been prepared by spray-drying may, after having been spray-dried, then be agglomerated with a solvent (such as those described above) to further improve the performance and physical characteristics of the resultant medium, supplement, subgroup or buffer,
  • a solvent such as those described above
  • an animal serum powder may be prepared by spray-drying liquid animal serum as described above, and this spray-dried serum powder may then be mixed into dry powder nutritive media (prepared by spray-drying or by standard techniques such as ball-milling); this mixed powder may then be agglomerated as described above.
  • a spray-dried nutritive medium, medium supplement, medium subgroup or buffer powder may be agglomerated as above, to improve the dissolution properties ofthe powder.
  • This approach may be particularly advantageous when spray-drying liquids with low (about 1-10%) solids content, such as liquid animal sera.
  • these approaches will facilitate preparation of a large batch of one or more components (e.g ., sera or other media supplements) to be used as a stock for addition to a powdered medium, supplement, subgroup or buffer at a desired concentration, while also obtaining the above-described benefits of agglomeration
  • this approach may reduce inter-lot variability which may be a problem with certain media supplements (particularly animal sera)
  • the agglomerated or spray-dried powdered nutritive media, media supplements, media subgroups or buffers prepared as described above may then be packaged, for example into containers such as vials, tubes, bottles, bags, pouches, boxes, cartons, drums and the like, prior to or following sterilization as described below.
  • the powdered media, media supplements, media subgroups or buffers may be packaged into a compact, vacuum-packed form, such as that known in the art as a "brick-pack" wherein the powder is packaged into a flexible container (such as a bag or a pouch) that is sealed while being evacuated.
  • Such packages may advantageously comprise one or more access ports (such as valves, luer-lock ports, etc.) allowing the introduction of a solvent (e.g., water, sera, media or other aqueous or organic solvents or solutions) directly into the package to facilitate rapid dissolution ofthe powder.
  • a solvent e.g., water, sera, media or other aqueous or organic solvents or solutions
  • the package may comprise two or more adjacent compartments, one or more ofwhich may contain one or more of the dry powder media, media supplements, media subgroups or buffers of the invention and one or more other of which may contain one or more aqueous or organic solvents which may be sterile
  • the dry powder may then be dissolved by simply removing or breaking the barrier between the compartments, ideally without loss of sterility, to allow admixture of the powder and the solvent such that the powder dissolves and produces a sterile nutritive medium, medium supplement, medium subgroup or buffer at a desired concentration
  • Packaged media, media supplements, media subgroups and buffers of the invention are preferably stored for the extended times, and at the temperatures, noted above, typically for about 1-24 months at temperatures of less than about 30°C, more preferably at temperatures of less than about 20-25°C, until use.
  • the invention also provides methods for sterilizing the nutritive media, media supplements, media subgroups and buffers of the invention, as well as for sterilizing powdered nutritive media, media supplements, media subgroups and buffers prepared by standard methods such as ball-milling or lyophilization. Since nutritive media, media supplements, media subgroups and buffers are usually prepared in large volume solutions and frequently contain heat labile components, they are not amenable to sterilization by irradiation or by heating. Thus, nutritive media, media supplements, media subgroups and buffers are commonly sterilized by contaminant-removal methods such as filtration, which significantly increases the expense and time required to manufacture such media, media supplements, media subgroups and buffers.
  • Powdered nutritive media, media supplements, media subgroups and buffers prepared according to the methods of the invention e.g ., by spray-drying of liquid media, media supplements, media subgroups or buffers, or by agglomeration of powdered media, media supplements, media subgroups or buffers), or by standard methods such as ball-milling (of powdered components) or lyophilization (ofliquid forms of the media, supplements, subgroups or buffers), however, can be sterilized by less expensive and more efficient methods.
  • powdered nutritive media, media supplements, media subgroups or buffers may be irradiated under conditions favoring sterilization of these powders
  • this irradiation is accomplished in bulk ( i.e ., following packaging of the nutritive media, media supplement, media subgroup or buffer), and most preferably this irradiation is accomplished by exposure of the bulk packaged media, media supplement, media subgroup or buffer of the invention to a source of gamma rays under conditions such that bacteria, fungi, spores or viruses that may be resident in the powdered media, media supplements, media subgroups or buffers are inactivated (i.e., prevented from replicating)
  • irradiation may be accomplished by exposure of the powdered media, media supplement, media subgroup or buffer, prior to packaging,
  • the media, media supplements, media subgroups and buffers of the invention may alternatively be sterilized by heat treatment (if the subgroups of the nutritive media, media supplement, media subgroup or buffer are heat stable), for example by flash pasteurization or autoclaving.
  • heat treatment if the subgroups of the nutritive media, media supplement, media subgroup or buffer are heat stable
  • flash pasteurization or autoclaving if the subgroups of the nutritive media, media supplement, media subgroup or buffer are heat stable
  • the dose of irradiation or heat, and the time of exposure, required for sterilization depend upon the bulk of the materials to be sterilized.
  • the bulk powdered nutritive media, media supplements, media subgroups or buffers are exposed to a source of ⁇ irradiation at a total dosage of about 10-100 kilograys (kGy), preferably a total dosage of about 15-75 kGy, 15-50 kGy, 15-40 kGy or 20-40 kGy, more preferably a total dosage of about 20-30 kGy, and most preferably a total dosage of about 25 kGy, for about 1 hour to about 7 days, more preferably about 1 hour to about 5 days, 1 hour to about 3 days, about 1-24 hours or about 1-5 hours, and most preferably about 1-3 hours ("normal dose rate").
  • kGy kilograys
  • the bulk powders of the invention may be sterilized at a "slow dose rate" of a total dosage of about 25-100 kGy over a period of about 1-5 days.
  • the powdered nutritive media, media supplements, media subgroups or buffers are preferably stored at a temperature of about -70°C to about room temperature (about 20-25°C), most preferably at about -70°C.
  • radiation dose and exposure times may be adjusted depending upon the bulk and/or mass of material to be irradiated; typical optimal irradiation dosages, exposure times and storage temperatures required for sterilization of bulk powdered materials by irradiation or heat treatment are well-known in the art.
  • unpackaged nutritive media, media supplements, media subgroups and buffers may be packaged under aseptic conditions, for example by packaging the media, media supplements, media subgroups or buffers into containers such as sterile tubes, vials, bottles, bags, pouches, boxes, cartons, drums and the like, or in the vacuum packaging or integrated powder/solvent packaging described above. Sterile packaged media, media supplements, media subgroups and buffers may then be stored for extended periods of time as described above.
  • the present invention thus provides powdered nutritive media, media supplements, media subgroups and buffers that are readily soluble in a rehydrating solvent and that are substantially dust free.
  • the agglomerated or spray-dried media, media supplement, media subgroup or buffer may be hydrated (or "reconstituted") in a volume of a solvent sufficient to produce the desired nutrient, electrolyte, ionic and pH conditions required for the particular use of the solvated media, media supplement, media subgroup or buffer.
  • Preferred solvents for use in reconstituting the powdered nutritive media, media supplements, media subgroups and buffers of the invention include, but are not limited to, water (most particularly distilled and/or deionized water), serum (particularly bovine or human serum and most particularly fetal bovine serum or calfserum), organic solvents (particularly dimethylsulfoxide, acetone, ethanol and the like), or any combination thereof, any of which may contain one or more additional components (e.g ., salts, polysaccharides, ions, detergents, stabilizers, etc.).
  • additional components e.g ., salts, polysaccharides, ions, detergents, stabilizers, etc.
  • powdered media supplements such as animal sera
  • buffers are preferably reconstituted in water to a 1X final concentration, or optionally to a higher concentration (e.g ., 2X, 2.5X, 5X, 10X, 20X, 25X, 50X, 100X, 500X, 1000X, etc.) for the preparation of stock solutions or for storage.
  • powdered culture media may be reconstituted in a solution of media supplements (e.g ., sera such as FBS) in water, such as those solutions wherein the media supplement is present at a concentration, for example, of 0.5%, 1%, 2%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 50%, or higher, vol/vol in the water
  • Reconstitution ofthe powdered nutritive media, media supplements, media subgroups or buffers is preferably accomplished under aseptic conditions to maintain the sterility of the reconstituted media, media supplement, media subgroup or buffer, although the reconstituted media, media supplement, media subgroup or buffer may alternatively be sterilized, preferably by filtration or other sterilization methods that are well-known in the art, following rehydration Following their reconstitution, media, media supplements, media subgroups and buffers should be stored at temperatures below about 10°C, preferably at temperatures of about 0-4°C, until use
  • the reconstituted nutritive media, media supplements, media subgroups and bluffers may be used to culture cells according to standard cell culture techniques which are well-known to one of ordinary skill in the art.
  • the cells to be cultured are contacted with the reconstituted media, media supplement, media subgroup or buffer of the invention under conditions favoring the cultivation of the cells (such as controlled temperature, humidity, lighting and atmospheric conditions).
  • Cells which are particularly amenable to cultivation by such methods include, but are not limited to, bacterial cells, yeast cells, plant cells and animal cells.
  • Such bacterial cells, yeast cells, plant cells and animal cells are available commercially from known culture depositories, e.g ., American Type Culture Collection (Rockville, Maryland), Invitrogen (La Jolla, California) and others that will be familiar to one of ordinary skill in the art, Preferred animal cells for cultivation by these methods include, but are not limited to, insect cells (most preferably Drosophil ⁇ cells, Spodoptera cells and Trichoplusa cells), nematode cells (most preferably C.
  • elegans cells and mammalian cells (including but not limited to CHO cells, COS cells, VERO cells, BHK cells, AE-1 cells, SP2/0 cells, L5.1 cells, hybridoma cells and most preferably human cells such as 293 cells, PER-C6 cells and HeLa cells), any of which may be a somatic cell, a germ cell, a normal cell, a diseased cell, a transformed cell, a mutant cell, a stem cell, a precursor cell or an embryonic cell, and any of which may be an anchorage-dependent or anchorage-independent (i.e., "suspension") cell.
  • mammalian cells including but not limited to CHO cells, COS cells, VERO cells, BHK cells, AE-1 cells, SP2/0 cells, L5.1 cells, hybridoma cells and most preferably human cells such as 293 cells, PER-C6 cells and HeLa cells
  • any of which may be a somatic cell, a germ cell, a normal cell, a
  • the invention in another aspect, relates to methods for producing dry cell powder compositions comprising one or more cells, and to dry cell powders produced by these methods These methods thus produce cell-containing compositions wherein the cells are preserved and may be stored for extended periods of time until use.
  • the methods of the invention overcome some of the drawbacks of traditional methods of cell preservation (e.g ., freezing) such as the need for cyropreservation equipment and the use of certain cryopreservatives that may be toxic to the cells.
  • Methods according to this aspect of the invention may comprise one or more steps.
  • one such method may comprise obtaining one or more cells to be dried, forming an aqueous cell suspension by suspending the one or more cells in an aqueous solution, and spray-drying the cell suspension under conditions favoring the production of a dried powder.
  • These methods may further comprise contacting the one or more cells with one or more stabilizing or preserving compounds (e.g ., a polysaccharide, including but not limited to trehalose).
  • the aqueous solution used to form the cell suspension preferably comprises one or more components, such as one or more of the above-described nutritive media, media supplements, media subgroups, salts or buffers.
  • the aqueous solution used to form the cell suspension is adjusted to optimal or substantially optimal tonicity and osmolality for the cell type being dried.
  • the aqueous solution may optionally comprise one or more additional components, such as one or more polysaccharides, ions, detergents, stabilizing or preserving compounds (including trehalose), and the like.
  • the stabilizing or preserving compounds may be incorporated into the aqueous solution used to form the aqueous cell suspension.
  • the stabilizing or preserving compounds may be sprayed or agglomerated onto the dry cell powder after formation of the powder.
  • the powder may optionally be agglomerated with a solvent according to methods described above for agglomeration of dry powders.
  • a solvent that is compatible with the cell type being dried may be used to agglomerate the dry cell powder, including but not limited to water, a nutritive medium solution, a nutritive medium supplement solution (including sera, particularly bovine sera (most particularly fetal bovine and calf sera) and human sera), a buffer solution, a salt solution, and combinations thereof.
  • a variety of cells may be dried according to the methods of the invention, including prokaryotic (e.g ., bacterial) and eukaryotic (e.g., fungal (especially yeast), animal (especially mammalian, including human) and plant) cells, particularly those cells, tissues, organs, organ systems, and organisms described above
  • prokaryotic e.g ., bacterial
  • eukaryotic e.g., fungal (especially yeast)
  • animal especially mammalian, including human
  • plant cells particularly those cells, tissues, organs, organ systems, and organisms described above
  • the dry cell powder may be aseptically reconstituted, into a cell suspension comprising one or more viable cells, with an aqueous solvent (e.g ., sterile water, buffer solutions, media supplements, culture media, or combinations thereof) and cultured according to standard art-known protocols
  • an aqueous solvent e.g ., sterile water, buffer solutions, media supplements, culture media, or combinations thereof
  • the dry cell powder may be reconstituted into a cell suspension where cell viability is not essential, for example for preparation of an immunogen to be used for immunization of an animal.
  • the dry cell powder may be reconstituted with any solvent that is compatible with standard immunization protocols, such as aqueous or organic solvents that may comprise one or more detergents, adjuvants, etc.
  • kits may comprise one or more containers such as vials, test tubes, bottles, packages, pouches, drums, and the like.
  • Each of the containers may contain one or more of the above-described nutritive media, media supplements, media subgroups or buffers of the invention, or combinations thereof.
  • Such nutritive media, media supplements, media subgroups or buffers may be hydrated or dehydrated but are typically dehydrated preparations produced by the methods of the invention.
  • Such preparations may, according to the invention, be sterile.
  • a first container may contain, for example, a nutritive media, media supplement, media subgroup or a buffer of the invention, or any component or subgroup thereof, such as any ofthose nutritive media, media supplements, media subgroups or buffers of the invention that are described above. Additional nutritive media, buffers, extracts, supplements, components or subgroups may be contained in additional containers in the present kits.
  • the kits may also contain, in one or more additional containers, one or more cells such as the above-described bacterial cells, yeast cells, plant cells or animal cells. Such cells may be lyophilized, dried, frozen or otherwise preserved, or may be spray-dried according to the methods ofthe invention.
  • kits of the invention may further comprise one or more additional containers, containing, for example, L-glutamine, optionally complexed with one or more divalent cations ( see U.S. Patent No. 5,474,931 ).
  • the kits may further comprise one or more additional containers containing a solvent to be used in reconstituting the dry powder nutritive media, media supplements, media subgroups and/or buffers; such solvents may be aqueous (including buffer solutions, saline solutions, nutritive medium solutions, nutritive medium supplement solutions (including sera such as bovine sera (particularly fetal bovine sera or calf sera) or human sera), or combinations thereof) or organic.
  • Other ingredients that are not compatible for admixture with the nutritive media, buffers, extracts, supplements, components or subgroups of the invention may be contained in one or more additional containers to avoid mixing of incompatible components.
  • kits for making a nutritive media, media supplement, media subgroup or buffer may vary depending on the type of media, media supplement, media subgroup or buffer to be prepared.
  • the kit will contain the respective containers containing the components or supplements necessary to make a particular media, media supplement, media subgroup or buffer.
  • additional containers may be included in the kit of the invention so that different media, media supplements, media subgroups or buffers can be prepared by mixing different amounts of various components, supplements, subgroups, buffers, solvents, etc, to make different media, media supplement, media subgroup or buffer formulations.
  • the present invention provides for the preparation of nutritive media, media supplements, media subgroups, buffers and cells at reduced cost
  • the cost reductions are due to the several factors.
  • the media, media supplement, media subgroup and buffer formulations of the present invention may be produced with much smaller production facilities since the large stir tanks required for 1X formulations are not required.
  • the media, media supplement, media subgroup and buffer formulations of the present invention may be prepared on an as needed basis using "just in time" production techniques which reduce inventory, storage and labor costs.
  • the time required for the preparation and shipping ofthe media, media supplement, media subgroup and buffer formulations may be reduced from 6-8 weeks to as little as one day.
  • the automatically pH-adjusting media of the invention also provide significant cost and time savings, and reduce the tendency for introduction of contamination into reconstituted media that may occur during the pH adjustment process according to standard methods using traditional dry powder or bulk liquid media.
  • the present invention also allows for the preparation of components of nutritive media, media supplements, media subgroups or buffers which may be used to prepare very large quantities of 1X media, media supplements, media subgroups or buffers ( e.g., 100,000 liters or more) which would require only one quality control test compared to multiple quality control tests for multiple batches produced according to other commonly used techniques.
  • the media, media supplement, media subgroup and buffer formulations of the present invention are more consistent between batches since the individual components are more stable.
  • the dried cell powders of the invention are also technologically and economically advantageous, since the cells may be stored, in low volume, for extended periods of time with little need for specialized equipment beyond that typically available in the laboratory.
  • the cells prepared by the present methods are preserved without being exposed to cryopreservative reagents which may be toxic to the cells.
  • Steps 5-8 should all be accomplished within one minute:
  • sodium bicarbonate is not typically added to DPM during manufacturing by ball-milling or lyophilization, due to potential off-gassing and buffering capacity complications encountered upon storage of the powdered media.
  • This standard production process thus necessitates the addition of sodium bicarbonate, and pH adjustment, upon reconstitution of the media.
  • these additional steps may be obviated by adding the sodium bicarbonate (or any buffering salt) directly to the powdered medium during manufacturing.
  • the amount of liquid to add is determined as follows: Prepare sodium bicarbonate at 75 g/L in water.
  • For each L of liquid assume (for example) a requirement of 2 g of sodium bicarbonate. This means that 50 g of bicarbonate is needed.
  • the bicarbonate solution is at 75 g/L, then 0.67 L of bicarbonate solution must be added to the 250 g of DPM.
  • the sodium bicarbonate solution would be added similarly to the process for "agglomeration of a typical DPM" above except that a longer drying time between cycles is needed since the pH ofthe sodium bicarbonate solution is ⁇ 8.00 which can degrade media components. It is important that the powder never become “soaked” by addition of bicarbonate solution too rapidly without allowing sufficient time for thorough drying of the bicarbonate powder between cycles, Also, longer fluid drying times are required since it is important to have as low a final moisture content as possible since moisture would result in liberation of carbon dioxide gas resulting in loss of buffering capacity and "pillow" formation if powder is in a foil packet.
  • Sodium bicarbonate can be milled into the DPM in a similar fashion as for other media components prior to fluid bed treatment. However, in the milling process, the bicarbonate should be added as the final component. All of the other media components should be milled as usual and then the mill stopped and the bicarbonate added last, with further milling to reach proper sized particles. It is important that all post-milling processing (placement into containers, etc.) be done in a humidity-controlled environment set as low as operationally possible ( ⁇ 20-40%. Fluid bed processing should then be performed as soon as possible after milling. (If not processed the same day, DPM must be double wrapped and placed within a sealed container with moisture absorbents.)
  • the fluid bed process itself is done similarly to the example given above (with use of 35 ml per 500 g of DPM) except that drying times after water injection (-6 ml/min) should again be extended: I min of injection of water and 2 minutes drying cycles. It will be noted that the color of the DPM will be deep red-light purple due to presence of phenol red. Since the DPM has essentially no moisture content, this does not represent a degradative situation, and is why fluid bed processing is essential.
  • Example 3 DPM that Includes Buffering Salts (e.g., Sodium Bicarbon ⁇ te) and is Formulated so that pH of Reconstituted (IX) Medium is Automatically of Desired pH with No User Efforts
  • Buffering Salts e.g., Sodium Bicarbon ⁇ te
  • any buffering salts or combinations thereof, and any acid or base may be used depending upon the desired pH and buffering capacity in the ultimately reconstituted cell culture medium
  • This 1N HCl must now be added to the DPM.
  • the best way for that is to use the injection device, adding 1N HCl instead of water.
  • the protocol is similar to the above with the following exceptions: (1) the 1N HCl must be added slowly to the media which contains sodium bicarbonate. If it is added too quickly, carbon dioxide may be driven off, resulting in suboptimal buffering capacity. Because of the volume of 1N HCl generally required, several I minute on, 2 minute off cycles are needed.
  • a dry powder state must be obtained at the end of each cycle so that a dynamic system exists where DPM has characteristics of a fluid process but in reality is a dried powder (Amazingly, as HCl is added to the powder, the bulk color changes from dark reddish purple to light yellow-orange color even though the powder remains essentially dry at all times due to the continual evaporation within the system). Since the total amount of HCl has been calculated to yield an essentially neutral pH, the powder is never really exposed to "acid" conditions as long as the fluid bed is properly adjusted (see above; position of the powder particles within the chamber during operation). It is important to make sure that all of the powder is moving through the system
  • the invention provides an automatic pH-adjusting dry powdered medium, where the pH of the liquid medium made by reconstituting the dry powdered medium requires no adjustment of pH.
  • Example 4 Inclusion of Large Molecular Weight Supplements Such as Serum, Albumin, Hy-Soy, etc., within the DPM Itself
  • the injection device of the fluid bed apparatus is able to form a mist with serum, and concentrated albumin We attempted to see if serum added to the DPM and dried in this manner would be functional.
  • Procedure for addition of serum (1) Determine the weight of standard DPM to be agglomerated. (2) From this, based upon the g/L for the particular powder, calculate the volume of 1X medium that the g of powder will make. (3) Calculate the volume of serum that would be needed at a given percentage level of supplementation (e.g ., 100 g of powder to be used in 10 g/L yields 10 L-equivalents of powder). At 5% serum supplementation, 500 ml of serum would be required to be added by the injection device.
  • Serum and albumin are very viscous
  • the nozzle spray pattern must be checked for droplet size and pattern. With the sample tube in the solution to be added to the powder, test spray against a cardboard or other backdrop Check for uniformity and small droplet size. If not a "mist,” increase atomizing pressure by 0.5 bar and test again. Do this until sufficient pressure results in a fine mist pattern.
  • Example 5 Reducing or Eliminating Milling Techniques (High Energy Input System That Break Components down to Mcron-sized Particles) When Manufacturing a DPM
  • dry powdered medium typically is manufactured via the milling process, which is laborious and has a number of problems.
  • the methods of the present invention provide for the production of a dry powdered medium using fluid bed technology, which overcomes these labor and technical constraints.
  • Normally milled DPM is blended with sodium bicarbonate (directly as received from the supplier, additional ball milling not needed) [RPM 1640 with sodium bicarbonate at 2 g/L-equivatents]. This mixture is blended for 20 minutes, The powder is then placed within the fluid bed chamber and fluidized as above for bicarbonate-containing media or bicarbonate-containing media with automatic pH control
  • Sodium bicarbonate is placed into the chamber directly with the milled DPM and blended (mixed) for a brief period of time, to be followed with agglomeration. This eliminates blending in a separate unit.
  • DPM chemicals are added directly to the fluid bed chamber and mixed preliminarily hollowed by agglomeration or, more likely, some of the coarser, "stickier”, etc chemicals are given a brief grinding treatment in a rotary grinder and then placed within the fluid bed for blending and final agglomeration.
  • a serum-containing DPM may be produced by combining a particular amount of DPM with a particular amount of powdered serum (prepared, e.g ., by spray-drying as described in Example 8 below) and then agglomerating the mixture.
  • powdered serum prepared, e.g ., by spray-drying as described in Example 8 below
  • agglomerating the mixture For example, for preparation of medium containing 10% powdered FBS, 55. 5 g powdered FBS may be added to 500 g of powdered culture medium and the powders mixed well by agitation. This mixture may then be water-agglomerated as described above, and will yield, upon reconstitution, a culture medium containing 10% FBS which may be auto-pH-adjusting.
  • Example 7 Production of 100% Serum Powder by Fluid Bed Processing (To Simul ⁇ te Spray-Drying)
  • the powdered serum was characterized with respect to its physical properties, compared to liquid FBS from the same source lot
  • Samples taken from different stages of the production lot (samples "A” and “B") were reconstituted at a concentration of 60 44 g/L in endotoxin-free distilled water (Life Technologies, Inc.), and were examined for endotoxin levels using a Limulus Amoebocyte Lysate test (Life Technologies, Inc.), for hemoglobin levels (by spectrophotometrically measuring absorbance at 525 nm), and by UV/Vis spectrophotometry, Results are shown in Table 1, and in Figures 3A and 3B . Table 1. Physical Characterization of Powdered Serum.
  • powdered FBS demonstrated endotoxin and hemoglobin levels similar to those of the liquid FBS that served as the source material for production of the powdered FBS. Moreover, samples taken from different stages of the production process demonstrated nearly identical endotoxin and hemoglobin levels, indicating that the present methods result in the production of material with approximately uniform physical consistency across the production lot.
  • Figure 3 samples of powdered and liquid FBS were examined by UV/visible spectrophotometry ( Figure 3 )
  • the trace observed for powdered FBS ( Figure 3A ) was indistinguishable from that obtained for the source liquid FBS ( Figure 3B ).
  • samples ofOpti-MEM ITM or DMEM were agglomerated with water or with FBS (2% only for Opti-MEM I; 2% or 10% for DMEM).
  • agglomerated powdered media Due to the open structure of the agglomerated powdered media (as opposed to traditional powdered media), capillary action brings water into close proximity with all of the powder particles This prevents the appearance of powder "balls, a complication observed upon reconstitution of most standard powdered media that leads to longer dissolution times" In addition to more rapid dissolution, agglomerated media demonstrated reduced dusting as well. These results indicate that water-agglomerated culture media, and some FBS-agglomerated culture media, are much more rapidly dissolving and generate less dust than traditional powdered culture media.
  • culture media were agglomerated with water or with various concentrations of FBS.
  • FBS was added to the powdered media by injecting it into the air-suspended dry powdered media at high evaporation rates, as generally outlined above.
  • the level of serum supplementation was 2% in Opti-MEM I media, and 2% or 10% in DMEM The growth and passage success of various cell lines in these media were then assessed.
  • SP2/0 cells demonstrated similar growth rates when grown in Opti-MEM I agglomerated with either water or with FBS ( Figure 6A ), compared to cells grown under conventional culture conditions (liquid serum added to water-reconstituted powdered media). Similar results were observed with SP2/0 cells cultured in water- and FBS-agglomerated DMEM supplemented with 2% FBS ( Figure 6B ), and with SP2/0 cells ( Figure 7A ), AE-1 cells ( Figure 7B ) and L5,1 cells ( Figure 7C ) cultured in water- and FBS-agglomerated DMEM supplemented with 10% FBS.
  • SP2/0 cells showed approximately similar recovery rates from passage when cultured in water- or agglomerated Opti-MEM I and DMEM supplemented with 2% FBS ( Figures 8A and 8B , respectively), as did SP2/0 cells, AE-1 cells and L5.1 cells cultured in water- and FBS-agglomerated DMEM supplemented with 10%FBS ( Figures 9A, 9B and 9C , respectively) and SP2/0 cells cultured in water-agglomerated DMEM supplemented with 5% FBS ( Figure 10 ). Furthermore, SP2/0 cells demonstrated identical passage characteristics in water-agglomerated media produced in large batches and in automatically pH-adjusting powdered DMEM containing sodium bicarbonate as they did in standard liquid DMEM supplemented with 5% FBS ( Figure 10 ).
  • culture media supplements such as animal sera (e.g., FBS) may be agglomerated directly into culture media, and that supplementation of culture media during the agglomeration process in this way produces a culture medium that provides optimal support of growth and passage of a variety of cultured cells.
  • present culture media powders may be successfully produced in large batches, including the automatically pH-adjusting media of the invention that contain sodium bicarbonate.
  • Example 12 Cell Growth in Culture Media Supplemented with Spray-Dried Serum Powder
  • AE-1 cells and SP2/0 cells were plated into DMEM containing either 2% or 10% spray-dried FBS prepared as described in Example 8, or containing 2% or 10% liquid FBS, and growth rates and passage recovery of the cells were examined.
  • Cells were inoculated into triplicate 25 cm 2 flasks at a density of 1 x 10 5 cells/ml in 10 ml of media Viable cell density was determined on days 3-7, and each cell line was tested twice Results are shown in Figures 11-13 .
  • AE-1 cells cultured in media containing powdered FBS demonstrated similar growth kinetics to those cells cultured in media containing standard liquid FBS. As expected, the cells demonstrated more rapid growth to a higher density in culture media containing 10% FBS than in media containing 2% FBS, and demonstrated peak growth by about day four. Similar kinetics were observed for two separate experiments ( Figures 11A and 11B ), indicating that these results were reproducible. Analogous results were obtained in two experiments in which the growth rates of SP2/0 cells were measured in media containing powdered or liquid FBS ( Figures 12A and 12B ). In addition, AE-1 cells cultured in media containing 5% powdered FBS recovered from passage with identical growth rates as cells in media containing liquid FBS ( Figure 13 ).
  • SP2/0 cells were inoculated into various media at 1 x 10 5 cells/ml and cultured at 37°C At various intervals, samples were obtained aseptically and cell counts determined by Coulter counting and viability determined by trypan blue exclusion, Media were prepared by dissolving sufficient powdered media to make a 1 X solution in 1L of water, stirring and filtering through a 0.22 ⁇ m filter Results are shown in the graph in Figure 14 .
  • VERO cells demonstrated approximately equivalent growth and passage success when cultured in agglomerated media that had been ⁇ -irradiated as in agglomerated media that had not been ⁇ -irradiated. Furthermore, irradiation of the media had no effect on the low-level culture supplements ELF and ferric citrate chelate that were present in the media.
  • ⁇ irradiation may be used as a sterilization technique in the preparation of many bulk agglomerated culture media, including those containing serum, EGF or other supplements, by the present methods.
  • lyophilized human holo-transferrin was irradiated by exposure to a cobalt ⁇ source at 25 kGy for about 3 days at -70 °C or at room temperature 293 cells were then cultured in media that were supplemented with irradiated transferrin or with control transferrin that had not been irradiated (stored at -70°C or at room temperature), and cell growth compared to that of standard transferrin- containing culture media or media that contained no transferrin.
  • Mid-log phase 293 cells that were growing in serum-free 293 medium (293 SFM) were harvested, washed once at 200 x g for 5 minutes and resuspended in transferrin-free 293 SFM for counting and viability determination.
  • Cells were plated into triplicate 125 ml Ehrlenmeyer flasks at a density of 3 x 10 5 cells/ml in a volume of 20 ml in 293 SFM (positive control), transferrin-free 293 SFM (negative control), in 293 SFM containing non-irradiated transferrin stored at -70°C or at room temperature, or in 293 SFM containing irradiated transferrin prepared as described above Flasks were placed into a rotary shaker set at about 125 rpm, in a 37°C incubator equilibrated with an atmosphere of 8% CO 2 /92% air.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP10175914.0A 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung Expired - Lifetime EP2281873B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4031497P 1997-02-14 1997-02-14
US5871697P 1997-09-12 1997-09-12
US6219297P 1997-10-16 1997-10-16
EP06002712A EP1702978B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung
EP98908542A EP1012234A4 (de) 1997-02-14 1998-02-17 Trockenzellen und zellkulturreagentien und verfahren zur deren herstellung

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
EP06002712A Division EP1702978B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung
EP98908542A Division EP1012234A4 (de) 1997-02-14 1998-02-17 Trockenzellen und zellkulturreagentien und verfahren zur deren herstellung
EP98908542.8 Division 1998-08-20
EP06002712.5 Division 2006-02-10

Publications (2)

Publication Number Publication Date
EP2281873A1 true EP2281873A1 (de) 2011-02-09
EP2281873B1 EP2281873B1 (de) 2014-07-23

Family

ID=27365699

Family Applications (4)

Application Number Title Priority Date Filing Date
EP10175914.0A Expired - Lifetime EP2281873B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung
EP98908542A Withdrawn EP1012234A4 (de) 1997-02-14 1998-02-17 Trockenzellen und zellkulturreagentien und verfahren zur deren herstellung
EP06002712A Expired - Lifetime EP1702978B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung
EP09180261.1A Expired - Lifetime EP2186882B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP98908542A Withdrawn EP1012234A4 (de) 1997-02-14 1998-02-17 Trockenzellen und zellkulturreagentien und verfahren zur deren herstellung
EP06002712A Expired - Lifetime EP1702978B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung
EP09180261.1A Expired - Lifetime EP2186882B1 (de) 1997-02-14 1998-02-17 Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung

Country Status (10)

Country Link
US (4) US6383810B2 (de)
EP (4) EP2281873B1 (de)
JP (8) JP4557311B2 (de)
AT (1) ATE507283T1 (de)
AU (1) AU6654998A (de)
CA (2) CA2798535C (de)
DE (1) DE69842243D1 (de)
DK (3) DK2281873T3 (de)
ES (1) ES2516790T3 (de)
WO (1) WO1998036051A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106783A1 (en) * 2015-12-17 2017-06-22 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
US10066200B2 (en) 2011-12-22 2018-09-04 Life Technologies Corporation Cell culture media and methods
JP2019500046A (ja) * 2015-12-30 2019-01-10 ライフ テクノロジーズ コーポレーション 層状の細胞培養粒子およびその製造方法

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US5362442A (en) * 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU2260097A (en) * 1996-03-12 1997-10-01 Life Technologies, Inc. Hematopoietic cell culture nutrient supplement
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
ES2241120T3 (es) 1997-02-12 2005-10-16 Invitrogen Corporation Metodos para liofilizar celulas competentes.
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20060003448A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
EP1091765A4 (de) * 1998-06-30 2001-10-24 Invitrogen Corp Verfahren zur reduzierung von zufällig auftretenden toxinen und dadurch produzierte zellkulturreagenzien
US6245555B1 (en) * 1998-09-01 2001-06-12 The Penn State Research Foundation Method and apparatus for aseptic growth or processing of biomass
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
FR2804326B1 (fr) * 2000-01-27 2002-10-18 Ellipse Pharmaceuticals Procede de sterilisation par traitement sous hautes pressions de principes actifs sensibles
EP1299131A4 (de) * 2000-03-23 2003-06-18 Clearant Inc Verfahren zum sterilisieren von biologischen materialien
US20040086420A1 (en) * 2000-03-23 2004-05-06 Macphee Martin J. Methods for sterilizing serum or plasma
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2001277230A1 (en) * 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
KR100385713B1 (ko) * 2000-08-30 2003-05-27 사회복지법인삼성생명공익재단(삼성서울병원) 면역병리 염색용 완충액
AU2002232406C1 (en) * 2000-11-06 2009-03-05 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
ATE356870T1 (de) * 2000-12-21 2007-04-15 Merck Patent Gmbh Verfahren zur herstellung von kompetenten oder transformierten zellen
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US6682695B2 (en) 2001-03-23 2004-01-27 Clearant, Inc. Methods for sterilizing biological materials by multiple rates
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US6946098B2 (en) 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US20030031584A1 (en) * 2001-08-10 2003-02-13 Wilson Burgess Methods for sterilizing biological materials using dipeptide stabilizers
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
AU2002331847A1 (en) * 2001-09-14 2003-04-01 Invitrogen Corporation Composition for stabilizing biological materials
US20110091353A1 (en) * 2001-09-24 2011-04-21 Wilson Burgess Methods for Sterilizing Tissue
US20030185702A1 (en) * 2002-02-01 2003-10-02 Wilson Burgess Methods for sterilizing tissue
US6783968B2 (en) * 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US20030095890A1 (en) * 2001-09-24 2003-05-22 Shirley Miekka Methods for sterilizing biological materials containing non-aqueous solvents
EP1438385A1 (de) * 2001-10-25 2004-07-21 Bar-Ilan University Interaktiver transparenter biochip-prozessor für einzeln adressierbare zellen
US8524279B2 (en) 2001-11-01 2013-09-03 Novartis Ag Spray drying methods and related compositions
JP2005530480A (ja) * 2001-11-30 2005-10-13 インヴィトロジェン コーポレーション 脂質を含む粉末細胞培養製品およびその製造法
US20030124023A1 (en) * 2001-12-21 2003-07-03 Wilson Burgess Method of sterilizing heart valves
US20030180181A1 (en) * 2002-02-01 2003-09-25 Teri Greib Methods for sterilizing tissue
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US6908591B2 (en) * 2002-07-18 2005-06-21 Clearant, Inc. Methods for sterilizing biological materials by irradiation over a temperature gradient
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
KR20050088243A (ko) * 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
US7033612B2 (en) * 2003-01-03 2006-04-25 Kang David S Composition and method for treating age-related disorders
IL154677A0 (en) * 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
CN1813059A (zh) * 2003-05-02 2006-08-02 西格玛-奥尔德利希公司 固相细胞裂解和捕获平台
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US8597597B2 (en) * 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
US7888110B2 (en) * 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
WO2004113492A1 (en) * 2003-06-26 2004-12-29 Molecular Cytomics Ltd. Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof
US7982751B2 (en) * 2003-07-11 2011-07-19 The University Of North Carolina Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
JP2007520546A (ja) * 2004-02-03 2007-07-26 ケマジス リミティド モンテルカストナトリウムの安定な非晶質性形態
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
EP1763665A1 (de) * 2004-07-07 2007-03-21 Seng Enterprises Limited Verfahren und vorrichtung zur identifizierung eines vertiefungsbildes auf einem bild einer komponente mit vertiefungen
WO2006026248A1 (en) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20080009051A1 (en) * 2004-08-25 2008-01-10 Seng Enterprises Ltd. Method and Device for Isolating Cells
ES2352344T3 (es) * 2005-01-25 2011-02-17 Seng Enterprises Limited Dispositivo de microfluido para estudio de células.
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
WO2007052245A1 (en) * 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
MX2011010633A (es) * 2009-04-09 2012-01-20 Entegrion Inc Productos sanguineos deshidratados por aspersion y metodos para elaborar los mismos.
SG185752A1 (en) * 2010-05-28 2013-01-30 Garnet Biotherapeutics Inc Compositions and methods of using living and non-living bioactive devices with components derived from self- renewing colony forming cells cultured and expanded in vitro
CN103313733A (zh) 2010-11-15 2013-09-18 捷迈整形外科生物材料有限公司 骨空隙填充剂
BR112013015213B1 (pt) 2010-12-16 2021-11-03 Merck Patent Gmbh Uso de um meio de cultura de células seco granulado
JP6143679B2 (ja) 2011-02-07 2017-06-07 ライフ テクノロジーズ コーポレーション 感受性化合物を安定化するための組成物および方法
DK2732027T3 (en) * 2011-07-12 2017-05-22 Foodchek Systems Inc CULTIVATION MEDIUM, METHOD OF CULTIVATING SALMONELLA AND E. COLI AND METHOD OF DETERMINING SALMONELLA AND E. COLI
EP2674482A1 (de) 2012-06-15 2013-12-18 Merck Patent GmbH Prozess zur Herstellung von Zellkulturmedien
US9765293B2 (en) 2012-07-25 2017-09-19 3M Innovative Properties Company Agglomerated microbiological media
WO2014025514A1 (en) 2012-08-07 2014-02-13 3M Innovative Properties Company Method of making agglomerated microbiological media and compositions thereof
CN105358674A (zh) * 2013-07-11 2016-02-24 默克专利有限公司 细胞培养基
WO2015126589A1 (en) 2014-02-21 2015-08-27 Life Technologies Corporation Systems, methods, and apparatuses for media rehydration
AU2015243961A1 (en) 2014-04-10 2016-10-27 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
KR101617858B1 (ko) * 2014-07-07 2016-05-04 유한책임회사 암브로티아 습식 과립화된 세포 배양 배지 및 그 제조방법
CN107208025A (zh) 2014-11-25 2017-09-26 康宁股份有限公司 延续细胞培养基的材料和方法
JP2018521682A (ja) * 2015-08-05 2018-08-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 細胞培養培地を生成するためのプロセス
WO2017223501A1 (en) * 2016-06-24 2017-12-28 AgBiome, Inc. Methods and compositions for spray drying gram-negative bacteria
JP2019521697A (ja) 2016-07-28 2019-08-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 水溶液中の成分の溶解挙動を改善するためのプロセス
US20200008299A1 (en) * 2016-10-21 2020-01-02 Bao Tran Flexible printed electronics
EP3875595A4 (de) * 2018-11-02 2022-07-13 Kyowa Kirin Co., Ltd. Verfahren zur herstellung eines flüssigen mediums
CN114555776A (zh) 2019-09-19 2022-05-27 生命技术公司 细胞培养基片剂和制造方法
KR20220097972A (ko) 2019-11-14 2022-07-08 메르크 파텐트 게엠베하 세포 배양 배지
JP2023507421A (ja) 2019-12-19 2023-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング タンパク質のグリコシル化プロファイルを調節するための方法および組成物
CA3182863A1 (en) 2020-06-22 2021-12-30 Life Technologies Corporation Methods and compositions for cultivating pluripotent cell suspensions
JP2023546222A (ja) 2020-10-21 2023-11-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
EP4261274A1 (de) 2022-04-13 2023-10-18 Merck Patent GmbH Meroxapolen für zellkultur
WO2024168086A1 (en) 2023-02-07 2024-08-15 Life Technologies Corporation Room-temperature-stable culture media and supplements
WO2024170622A1 (en) 2023-02-16 2024-08-22 Merck Patent Gmbh Cell culture media

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3771237A (en) 1971-04-16 1973-11-13 Niro Atomizer As Device for drying damp powders
US4490403A (en) * 1982-06-14 1984-12-25 A/S Niro Atomizer Process for producing an agglomerated powdery milk product
US4511592A (en) 1982-03-11 1985-04-16 Scm Corporation Preparation of acidulated meat emulsions
EP0155427A1 (de) * 1984-02-09 1985-09-25 Societe D'applications Pharmaceutiques Et Biologiques Hoechst-Behring Gebrauchsfertiger schnellauflöslicher fester Nährboden und Verfahren zu seiner Herstellung
US4673649A (en) 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US4689297A (en) 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4885848A (en) 1987-07-14 1989-12-12 A/S Niro Atomizer Fluid bed dryer and a bed plate therefor
JPH0257175A (ja) * 1988-08-19 1990-02-26 Morinaga & Co Ltd 成形培地及びその製造法
US5006204A (en) 1988-08-10 1991-04-09 A/S Niro Atomizer Apparatus for crystallizing whey
US5133137A (en) 1990-02-08 1992-07-28 Niro A/S Method and apparatus for heat treating a particulate product
DK167090B1 (da) 1975-04-23 1993-08-30 Glatt Ingtech Gmbh Hvirvellagsapparat
US5325606A (en) 1992-12-23 1994-07-05 Niro A/S Process and apparatus for drying and calcining sodium bicarbonate
US5357688A (en) 1990-09-11 1994-10-25 Niro A/S Method and apparatus for treating a pulverulent or particulate material or product with gas
US5392531A (en) 1991-04-05 1995-02-28 Niro Holding A/S Bed plate for a fluidized bed apparatus and a method for making the same
WO1995013865A1 (en) * 1993-11-15 1995-05-26 Niro Holding A/S An apparatus and a process for the preparation of an agglomerated material
WO1995013867A1 (en) 1993-11-15 1995-05-26 Niro Holding A/S Fluid bed for producing and/or processing a particulate material
US5474931A (en) 1991-06-17 1995-12-12 Life Technologies, Inc. Media concentrate technology

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1355192U (de)
US2835586A (en) 1953-07-27 1958-05-20 Instant Milk Company Dried milk product and method of making same
NL6601640A (de) 1965-02-11 1966-08-12
DE1949690A1 (de) 1969-10-02 1971-04-08 Egon Laumen Behaelter,insbesondere Milchbeutel,aus Kunststoffolie
DK123067B (da) 1970-09-25 1972-05-15 Niro Atomizer As Fremgangsmåde til behandling af et pulverformigt, fedtholdigt mælkeprodukt.
GB1355192A (en) * 1970-12-21 1974-06-05 Niro Atomizer As Methods for producing agglomerated coffee powder and other powders and apparatus for carrying out the method
US4072570A (en) 1972-04-11 1978-02-07 Beatrice Foods Co. Preparation of a tuberculosis test medium by reconstituting a storage stabilized dry powdered Lowenstein-Jensen medium
CS169007B1 (de) 1973-05-18 1976-06-29
US4073951A (en) 1974-04-18 1978-02-14 Sargeant Ralph G Agglomeration method
IL44853A (en) 1974-05-17 1975-11-25 Isorad Isotopes & Radiation Process for the preparation of sterile culture media and culture medium thus obtained
US3920857A (en) * 1974-10-21 1975-11-18 Central Soya Co Method of preparing a granular free-flowing lecithin product
JPS5652542B2 (de) 1975-02-24 1981-12-12
US4053542A (en) 1976-07-22 1977-10-11 Acf Industries, Inc. Control means for secondary throttle
US4282326A (en) 1978-10-12 1981-08-04 Jeanne Moldenhauer Cell culture medium supplement
US4241186A (en) 1978-12-18 1980-12-23 Conviron, Inc. Pectin culture media and method
US4282255A (en) 1979-06-28 1981-08-04 State Of Oregon, By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method and starter compositions for the growth of acid producing bacteria and bacterial compositions produced thereby
US4615978A (en) 1979-06-28 1986-10-07 The State Of Oregon, By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Bacterial growth medium and method of use
EP0049632B1 (de) 1980-10-06 1985-07-03 Chlorella Industry Co., Ltd Zellkulturverfahren
JPS57152882A (en) 1981-03-14 1982-09-21 Kikujiro Ishiwatari Method for killing living general chlorella
JPS57206398A (en) 1981-06-15 1982-12-17 Eiken Kagaku Kk Dried culture medium for identifying cell
US4416898A (en) 1982-03-01 1983-11-22 Pharmuka Laboratoires Therapeutic uses of methionine
JPH07105474B2 (ja) 1983-09-28 1995-11-13 株式会社日立製作所 半導体メモリ
US4544637A (en) 1982-09-14 1985-10-01 Igi Biotechnology, Inc. Culture media from clarified diary whey lactose permeates
DD228951A3 (de) * 1982-12-02 1985-10-23 Inst Getreideverarbeitung Verfahren zur herstellung von granulierter nahrung
US4511593A (en) 1983-01-17 1985-04-16 Multi-Arc Vacuum Systems Inc. Vapor deposition apparatus and method
SU1097253A1 (ru) 1983-02-25 1984-06-15 Опытное Конструкторско-Технологическое Бюро По Интенсификации Тепломассообменных Процессов Способ получени сухого ацидофильного препарата
JPS59501933A (ja) 1983-03-02 1984-11-22 アイジ−アイ、バイオテクノロジ−、インコ−ポレイテッド 清澄化した酪産乳漿ラクト−ス透過物を培地および他の商業的に有用な製品への転換
US4621058A (en) 1983-04-11 1986-11-04 Mid-America Dairymen, Inc. Method of preparing cheese starter media
US4620908A (en) 1983-10-03 1986-11-04 Biocell Laboratories, Inc. Method for destroying microbial contamination in protein materials
US4632980A (en) 1985-04-03 1986-12-30 Immunologics Ozone decontamination of blood and blood products
US4975246A (en) 1985-09-30 1990-12-04 Charm Stanley E High temperature, short time heating system and method of heating heat-sensitive material
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
GB8620003D0 (en) 1986-08-16 1986-09-24 Arbuthnoit R D Accessory device
JPH067791B2 (ja) 1986-12-12 1994-02-02 農薬バイオテクノロジ−開発技術研究組合 オ−トクレ−ブ滅菌無血清培地による昆虫細胞の培養法
GB8700354D0 (en) 1987-01-08 1987-02-11 Distillers Co Culture of micro-organisms
EP0283942B1 (de) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basisnährmedium für eine Zellkultur
US4848122A (en) * 1987-07-20 1989-07-18 Chemtronics Method and apparatus for deburring using shot
GB8718756D0 (en) 1987-08-07 1987-09-16 Unilever Plc Supporting means
JPH0646941B2 (ja) * 1987-12-11 1994-06-22 サントール株式会社 微生物の培養法
GB8800572D0 (en) 1988-01-12 1988-02-10 Red Baron Oil Tools Rental Improvements in/relating to drilling tool
NO901662L (no) 1989-04-17 1990-12-21 Monsanto Co Toert herbicid preparat med forbedret vannopploeselighet.
US5254073A (en) 1990-04-27 1993-10-19 Kapak Corporation Method of making a vented pouch
JPH0761259B2 (ja) 1990-10-08 1995-07-05 工業技術院長 酵母細胞内物質の抽出法
JPH04198137A (ja) 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 無菌乾燥炭酸ナトリウムの製法
JP2895641B2 (ja) * 1991-02-28 1999-05-24 ハウス食品株式会社 動物細胞増殖促進剤及びそれを用いた動物細胞増殖方法
US5700426A (en) 1991-03-08 1997-12-23 Foundation Nationale De Transfusion Sanguine Method for decontaminating or sterilizing "in situ" a vacuum sealed container and device for implementing such method
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US5155039A (en) 1991-07-22 1992-10-13 Chrisope Technologies, Inc. Apparatus for methods for preserving, transporting storing, re-hydrating and delivering viable micro-organisms
US5445792A (en) 1992-03-13 1995-08-29 American Sterilizer Company Optimum hydrogen peroxide vapor sterlization method
US5366696A (en) 1993-01-07 1994-11-22 1077075 Ontario Inc. Oxygenation apparatus for oxygenating a carrier liquid by spraying
AU4399693A (en) * 1993-05-28 1994-12-20 Porton International Plc System for packaging and delivering of a sterile powder medium
GEP19981338B (en) 1993-06-15 1998-08-25 Commonwealth Scient And Industrial Reserch Organisation Method for Fumigation of Particulate Commodities in Storehouse and Devise for its Conducting
DK75293D0 (da) 1993-06-24 1993-06-24 Anhydro As Fremgangsmaade og anlaeg til et agglomereret produkt
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5563068A (en) 1994-04-21 1996-10-08 Genetic Therapy, Inc. Bioreactor
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5662897A (en) 1994-07-27 1997-09-02 U. Of Ga Research Foundation Insect viruses, sequences, insecticidal compositions and methods of use
US5733774A (en) * 1995-02-02 1998-03-31 Ecoscience Corporation Method and composition for producing stable bacteria and bacterial formulations
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
JPH11513248A (ja) * 1995-09-18 1999-11-16 ミネソタ・マイニング・アンド・マニュファクチャリング・カンパニー 顆粒状培地粒子を含む薄膜培養プレート装置
DE19535581C1 (de) * 1995-09-25 1996-10-31 Cpc Maizena Gmbh Verfahren zur Herstellung von Eierstich
US6140121A (en) 1995-10-19 2000-10-31 Advanced Reproduction Technologies, Inc. Methods and compositions to improve germ cell and embryo survival and function
SE507856C2 (sv) 1996-04-12 1998-07-20 Acanova Ab Värmesanering av fröer
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5773279A (en) 1996-11-27 1998-06-30 Neogen Corporation Culture medium and method for repair of microbial cells
US20060003448A1 (en) 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20040022666A1 (en) 1998-06-30 2004-02-05 Invitrogen Corporation Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby
US6627426B2 (en) 1997-02-14 2003-09-30 Invitrogen Corporation Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby
US6210715B1 (en) 1997-04-01 2001-04-03 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US6045838A (en) 1998-08-10 2000-04-04 Davis; Harold L. Grape handling and storage bag
US6206571B1 (en) 1999-06-24 2001-03-27 Alan D. Olin Flexible bag with resealable pour spout
AU2002232406C1 (en) 2000-11-06 2009-03-05 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
JP2005530480A (ja) 2001-11-30 2005-10-13 インヴィトロジェン コーポレーション 脂質を含む粉末細胞培養製品およびその製造法

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3771237A (en) 1971-04-16 1973-11-13 Niro Atomizer As Device for drying damp powders
DK167090B1 (da) 1975-04-23 1993-08-30 Glatt Ingtech Gmbh Hvirvellagsapparat
US4511592A (en) 1982-03-11 1985-04-16 Scm Corporation Preparation of acidulated meat emulsions
US4490403A (en) * 1982-06-14 1984-12-25 A/S Niro Atomizer Process for producing an agglomerated powdery milk product
US4673649A (en) 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
EP0155427A1 (de) * 1984-02-09 1985-09-25 Societe D'applications Pharmaceutiques Et Biologiques Hoechst-Behring Gebrauchsfertiger schnellauflöslicher fester Nährboden und Verfahren zu seiner Herstellung
US4689297A (en) 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4885848A (en) 1987-07-14 1989-12-12 A/S Niro Atomizer Fluid bed dryer and a bed plate therefor
US5006204A (en) 1988-08-10 1991-04-09 A/S Niro Atomizer Apparatus for crystallizing whey
JPH0257175A (ja) * 1988-08-19 1990-02-26 Morinaga & Co Ltd 成形培地及びその製造法
US5133137A (en) 1990-02-08 1992-07-28 Niro A/S Method and apparatus for heat treating a particulate product
US5357688A (en) 1990-09-11 1994-10-25 Niro A/S Method and apparatus for treating a pulverulent or particulate material or product with gas
US5392531A (en) 1991-04-05 1995-02-28 Niro Holding A/S Bed plate for a fluidized bed apparatus and a method for making the same
US5474931A (en) 1991-06-17 1995-12-12 Life Technologies, Inc. Media concentrate technology
US5325606A (en) 1992-12-23 1994-07-05 Niro A/S Process and apparatus for drying and calcining sodium bicarbonate
WO1995013865A1 (en) * 1993-11-15 1995-05-26 Niro Holding A/S An apparatus and a process for the preparation of an agglomerated material
WO1995013867A1 (en) 1993-11-15 1995-05-26 Niro Holding A/S Fluid bed for producing and/or processing a particulate material

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Methods For Preparation of Media, Supplements and Substrate For Serum-Free Animal Cell Culture", 1984, ALLEN R. LISS
BARRETAULT, D. ET AL., DIFFERENTIATION, vol. 18, 1981, pages 29 - 42
COHEN, S., J. BIOL. CHEM., vol. 237, 1961, pages 1555 - 1565
DATABASE WPI Section Ch Week 199014, Derwent World Patents Index; Class D16, AN 1990-104911, XP002395623 *
DUE JENSEN J.: "Agglomerating, Instantizing, and Spray Drying", FOOD TECHNOLOGY, vol. 29, no. 6, June 1975 (1975-06-01), pages 60 - 71, XP002210006 *
FRESHNEY, R.I.: "Culture of Animal Cells", 1983, ALAN R. LISS, INC, pages: 74 - 78
GILCHREST, B.A. ET AL., J. CELL. PHYSIOL., vol. 120, 1984, pages 377 - 383
HARLOW, E.; LANE, D.: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY, pages: 116 - 120
LAMBERT, K.J. ET AL.: "Animal Cell Biotechnology", vol. 1, 1985, ACADEMIC PRESS, pages: 85 - 122
LIFE TECHNOLOGIES: "GIBCO-BRL 1996-1997 Catalogue for Cell culture", 1996, THOMSON PRINT SERVICES LIMITED, GLASGOW, SCOTLAND, XP002210007 *
MACIAG, T ET AL., SCIENCE, vol. 211, 1981, pages 1452 - 1454
MACIAG, T. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 5674 - 5678
PEEHL, D.M.; HAM, R.G., IN VITRO, vol. 16, 1980, pages 516 - 525
RINGER, S., J PHYSIOL., vol. 3, pages 380 - 393
TRITSCH ET AL., EXP. CELL RES., vol. 28, 1962, pages 360 - 364
WANG ET AL., IN VITRO, vol. 14, no. 8, 1978, pages 715 - 722
WAYMOUTH, C., IN VITRO, vol. 6, 1970, pages 109 - 127
WAYMOUTH, C.: "Cells and Tissues in Culture", vol. 1, 1965, ACADEMIC PRESS, pages: 99 - 142

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066200B2 (en) 2011-12-22 2018-09-04 Life Technologies Corporation Cell culture media and methods
EP2794853B1 (de) * 2011-12-22 2020-04-22 Life Technologies Corporation Zellkulturmedien und verfahren
EP3702442A1 (de) * 2011-12-22 2020-09-02 Life Technologies Corporation Zellkulturmedien und verfahren
WO2017106783A1 (en) * 2015-12-17 2017-06-22 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
CN108495926A (zh) * 2015-12-17 2018-09-04 生命技术公司 用于细胞培养的颗粒及其制备方法
US10822584B2 (en) 2015-12-17 2020-11-03 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
JP2019500046A (ja) * 2015-12-30 2019-01-10 ライフ テクノロジーズ コーポレーション 層状の細胞培養粒子およびその製造方法

Also Published As

Publication number Publication date
JP4557311B2 (ja) 2010-10-06
JP2009118864A (ja) 2009-06-04
ATE507283T1 (de) 2011-05-15
JP5985463B2 (ja) 2016-09-06
JP2008043343A (ja) 2008-02-28
DK2281873T3 (da) 2014-10-27
US7572632B2 (en) 2009-08-11
EP1702978A3 (de) 2006-10-04
EP1702978B1 (de) 2011-04-27
US20120276630A1 (en) 2012-11-01
EP2281873B1 (de) 2014-07-23
JP2010233580A (ja) 2010-10-21
JP2007125044A (ja) 2007-05-24
DK2186882T3 (en) 2015-04-27
DK1702978T3 (da) 2011-05-30
EP1012234A1 (de) 2000-06-28
CA2280741C (en) 2013-04-09
EP2186882B1 (de) 2015-01-28
CA2280741A1 (en) 1998-08-20
JP2016152821A (ja) 2016-08-25
US6383810B2 (en) 2002-05-07
EP2186882A1 (de) 2010-05-19
WO1998036051A1 (en) 1998-08-20
DE69842243D1 (de) 2011-06-09
EP1012234A4 (de) 2002-11-06
US20040087022A1 (en) 2004-05-06
US20130065300A1 (en) 2013-03-14
AU6654998A (en) 1998-09-08
JP2014054267A (ja) 2014-03-27
CA2798535C (en) 2016-05-17
US20010049141A1 (en) 2001-12-06
ES2516790T3 (es) 2014-10-31
EP1702978A2 (de) 2006-09-20
CA2798535A1 (en) 1998-08-20
JP2005118046A (ja) 2005-05-12
JP2002515758A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
EP2281873B1 (de) Trockenzellen und Zellkulturreagentien und Verfahren zur deren Herstellung
AU2002232406C1 (en) Dry powder cells and cell culture reagents and methods of production thereof
US6627426B2 (en) Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby
AU2002232406A1 (en) Dry powder cells and cell culture reagents and methods of production thereof
US20060270038A1 (en) Dry powder cell culture products containing lipid and methods of production thereof
US20060003448A1 (en) Dry powder cells and cell culture reagents and methods of production thereof
US20040022666A1 (en) Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby
US20060003447A1 (en) Dry powder cells and cell culture reagents and methods of production thereof
CA2329283C (en) Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1702978

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1012234

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20110809

17Q First examination report despatched

Effective date: 20111121

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 1/14 20060101ALI20131003BHEP

Ipc: C12N 1/20 20060101ALI20131003BHEP

Ipc: C12N 1/16 20060101ALI20131003BHEP

Ipc: C12N 5/00 20060101AFI20131003BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140108

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1702978

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1012234

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 678905

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69843279

Country of ref document: DE

Effective date: 20140904

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MEYER AND KOLLEGEN, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20141022

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2516790

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20141031

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141024

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141124

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69843279

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140723

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140723

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170112

Year of fee payment: 20

Ref country code: DE

Payment date: 20170214

Year of fee payment: 20

Ref country code: CH

Payment date: 20170214

Year of fee payment: 20

Ref country code: SE

Payment date: 20170213

Year of fee payment: 20

Ref country code: FI

Payment date: 20170209

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20170210

Year of fee payment: 20

Ref country code: IE

Payment date: 20170209

Year of fee payment: 20

Ref country code: BE

Payment date: 20170113

Year of fee payment: 20

Ref country code: GB

Payment date: 20170215

Year of fee payment: 20

Ref country code: NL

Payment date: 20170210

Year of fee payment: 20

Ref country code: AT

Payment date: 20170125

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20170112

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69843279

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20180217

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20180216

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20180216

Ref country code: BE

Ref legal event code: FP

Effective date: 20141016

Ref country code: BE

Ref legal event code: MK

Effective date: 20180217

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 678905

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180216

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180217

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180218